1. Introduction {#sec1-molecules-25-02734}
===============

Penile erection is started from the sexual stimulation which causes the release of nitric oxide (NO) from nerves and cells in the penis. The released NO diffuses into the cells and activates guanylyl cyclase synthesizing cyclic GMP (cGMP). cGMPs, an intra-cellular second messenger, cause the smooth muscle of corpus cavernosum to relax, which in turn promotes inflow of blood, and ultimately, compression of the spongy corpus cavernosum tissue. This compression results in penile erection \[[@B1-molecules-25-02734]\]. Phosphodiesterase type 5 (PDE-5) is a primary hydrolytic enzyme that is localized mainly in the human corpus cavernosum tissue. It plays a major biological role in the hydrolysis of cyclic guanosine monophosphate (cGMP) to 5′-GMP. PDE-5 inhibitors such as sildenafil (Viagra, Pfizer, New York, NY, USA), vardenafil (Levitra, Bayer, Leverkusen, Germany), tadalafil (Cialis, Elli Lilly, Indianapolis, IN, USA), mirodenafil (Mvix, SK Life Science, Seongnam, Republic of Korea), and udenafil (Zydena, Dong-A Pharmaceutical, Seoul, Republic of Korea) compete with cGMP for the catalytic sites composed of 16 helices and 16 loops at the C-terminal end (amino acid residues:535--860) \[[@B2-molecules-25-02734]\] of the PDE-5 enzyme and retard the enzymatic hydrolysis of cGMP in the corpus cavernosum, which eventually leads to penile erection \[[@B1-molecules-25-02734]\]. Thus, PDE-5 inhibitors are used for the treatment of erectile dysfunction (ED).

Patients over the age of 40 suffering from chronic diseases such as hypertension, ischemic heart disease, depression, diabetes, and atherosclerosis commonly complain of ED as a complication \[[@B1-molecules-25-02734]\]. However, the drugs for the treatment of these chronic diseases, such as nitroglycerin, doxazosin, and terazosin, interact negatively with PDE-5 inhibitors \[[@B3-molecules-25-02734]\]. This negative aspect of synthetic PDE-5 inhibitors has triggered the development of herbal alternatives. Thus, herbal therapies have successfully captured the market because most people believe that they are safe from adverse effects, and they can be purchased without any prescription \[[@B3-molecules-25-02734],[@B4-molecules-25-02734],[@B5-molecules-25-02734]\]. However, taking advantage of the recognition that natural products are safe, illegally adding synthetic PDE-5 inhibitors and their analogs to herbal dietary supplements or making counterfeit drugs began to be distributed \[[@B6-molecules-25-02734],[@B7-molecules-25-02734],[@B8-molecules-25-02734],[@B9-molecules-25-02734],[@B10-molecules-25-02734],[@B11-molecules-25-02734],[@B12-molecules-25-02734]\]. Since the detection of the first sildenafil analog, homosildenafil, in dietary supplements, the number of analogs has steadily increased owing to various structural modifications of the original drugs \[[@B5-molecules-25-02734],[@B6-molecules-25-02734]\].

As the structure of these analogs is similar to that of the original drugs, their pharmacological effects are similar to those of the final developed drugs except for their potency, side effects, and toxicity. Therefore, the adulterated analogs in dietary supplements may pose significant pharmacological and toxicological risks such as headaches, dyspepsia, myalgia, flushing, dizziness, and abnormal vision \[[@B5-molecules-25-02734],[@B13-molecules-25-02734]\]. For example, hongdenafil analogs cause visual disturbances even in low doses because hongdenafil lacks PDE-5/PDE-6 selectivity \[[@B5-molecules-25-02734],[@B14-molecules-25-02734],[@B15-molecules-25-02734]\]. In addition, aminotadalafil has a reactive hydrazone group that permanently inhibits the enzymes \[[@B5-molecules-25-02734],[@B14-molecules-25-02734]\]. Therefore, undeclared PDE-5 inhibitors and their analogs in dietary supplements threaten public health.

The analytical methods for determining undeclared PDE-5 inhibitors and their analogs in dietary supplements need to be developed for public health safety and regulation. In this regard, various spectrometric and chromatographic methods have been adopted to analyze the illegally added drugs in complex matrices \[[@B3-molecules-25-02734],[@B4-molecules-25-02734],[@B5-molecules-25-02734],[@B9-molecules-25-02734],[@B16-molecules-25-02734],[@B17-molecules-25-02734],[@B18-molecules-25-02734],[@B19-molecules-25-02734],[@B20-molecules-25-02734],[@B21-molecules-25-02734],[@B22-molecules-25-02734],[@B23-molecules-25-02734],[@B24-molecules-25-02734],[@B25-molecules-25-02734],[@B26-molecules-25-02734],[@B27-molecules-25-02734],[@B28-molecules-25-02734],[@B29-molecules-25-02734]\]. High-performance liquid chromatography with diode array detection (HPLC--DAD) and liquid chromatography with mass spectrometry (LC--MS) have been previously used to detect PDE-5 inhibitors and their analogs \[[@B3-molecules-25-02734],[@B5-molecules-25-02734],[@B7-molecules-25-02734],[@B8-molecules-25-02734],[@B9-molecules-25-02734],[@B10-molecules-25-02734],[@B16-molecules-25-02734],[@B17-molecules-25-02734],[@B20-molecules-25-02734],[@B21-molecules-25-02734],[@B22-molecules-25-02734],[@B23-molecules-25-02734],[@B24-molecules-25-02734],[@B25-molecules-25-02734],[@B26-molecules-25-02734],[@B27-molecules-25-02734],[@B28-molecules-25-02734],[@B29-molecules-25-02734],[@B30-molecules-25-02734],[@B31-molecules-25-02734],[@B32-molecules-25-02734],[@B33-molecules-25-02734],[@B34-molecules-25-02734]\]. When the standards of PDE-5 inhibitors and their analogs are available, HPLC with a UV spectrometer is a simple method for quantitative analysis \[[@B11-molecules-25-02734]\]. In HPLC--DAD, the analytes can be identified by comparing the UV spectra of the reference compounds and analytes of interest \[[@B3-molecules-25-02734],[@B10-molecules-25-02734],[@B17-molecules-25-02734],[@B33-molecules-25-02734]\]. In this context, MS has attracted considerable interest for both qualitative and quantitative analysis. Particularly in quantitative analysis, multiple reaction monitoring (MRM) in triple quadrupole mass spectrometry (QqQ MS) shows unique selectivity with high sensitivity. Thus, QqQ MS is usually used to detect analytes in complex matrices using MRM with a unique ion transition of the analytes \[[@B16-molecules-25-02734],[@B20-molecules-25-02734],[@B22-molecules-25-02734],[@B32-molecules-25-02734]\]. Although DAD provides the UV spectra of certain compounds identified in a given chromatogram, there are no authentic UV spectra of newly synthesized PDE-5 inhibitors. Further, QqQ MS can only be used for the quantitative analysis of known compounds and not for screening purposes. Therefore, other spectroscopic methods such as high-resolution mass spectrometry (HRMS) based on Fourier transform ion cyclotron resonance (FT-ICR) \[[@B31-molecules-25-02734]\], time of flight (TOF) \[[@B24-molecules-25-02734],[@B25-molecules-25-02734],[@B28-molecules-25-02734],[@B29-molecules-25-02734],[@B33-molecules-25-02734]\], orbitrap \[[@B8-molecules-25-02734],[@B12-molecules-25-02734],[@B26-molecules-25-02734],[@B27-molecules-25-02734]\], and nuclear magnetic resonance spectrometry \[[@B4-molecules-25-02734],[@B6-molecules-25-02734],[@B7-molecules-25-02734],[@B9-molecules-25-02734],[@B30-molecules-25-02734],[@B34-molecules-25-02734],[@B35-molecules-25-02734],[@B36-molecules-25-02734],[@B37-molecules-25-02734],[@B38-molecules-25-02734]\] must be applied to clarify the structure of the analytes. In particular, hybrid ion trap (IT)--HRMS, including IT--TOF and Orbitraps (LTQ--Orbitrap and Orbitrap Fusions), is one of the most effective tools for screening and identification of unknown compounds owing to its high-resolution and multistage tandem MS (MS^n^) ability. The MS^n^ ability of the IT--HRMS provides more structural information than does QqQ MS by sequential trapping and fragmentation of the precursor ion, and accurate masses of both parent and fragment ions can be obtained by HRMS for further conversion into elemental composition.

In this study, we developed a screening method for adulterated PDE-5 inhibitors and their analogs in dietary supplements by using HPLC coupled to IT--TOF MS. The HPLC separation conditions such as mobile phase and gradient, and MS parameters were optimized for the best chromatographic resolution and for obtaining tandem MS spectra with rich information about the parent and fragment ions. In addition, a spectral library for 38 PDE-5 inhibitors and their analogs was built using the high-resolution tandem MS spectra obtained in this study. The developed method was applied to dietary supplements that were adulterated with PDE-5 inhibitors and their analogs. We could successfully identify the illegally fortified PDE-5 inhibitors using the spectral library.

2. Results and Discussion {#sec2-molecules-25-02734}
=========================

2.1. HPLC--MS Method Development {#sec2dot1-molecules-25-02734}
--------------------------------

As the selected precursor ions for MS^n^ analysis are isolated and undergo collision-induced dissociation (CID) in IT MS, wherein the analysis is performed at the unit mass resolution, chromatographic separation is prerequisite for the simultaneous qualification of isobaric compounds. In this study, different stationary phases were tested to optimize the separation of isobaric compounds from mixtures of 38 standards of PDE-5 inhibitors and their analogs. The separation of isobaric compounds among three different stationary phases was compared. The Capcell PAK C18 column showed the best chromatographic separation performance and was hence selected for LC--MS analysis.

Various mobile phase additives, including formic acid, acetic acid, ammonium formate, and ammonium acetate, were investigated for the separation of isobaric compounds. Although formic acid, ammonium formate, and ammonium acetate showed better separation than acetic acid, they negatively affected the MS sensitivity. Sensitivity, which is mainly affected by the ionization conditions, is imperative for the identification of unknown compounds in MS^n^ analysis. Thus, acetic acid was chosen as the mobile phase additive to improve the MS sensitivity. Between two different concentrations (0.1% and 0.2%) of acetic acid, 0.2% acetic acid gave better separation efficiency. Considering the ionization efficiency and chromatographic separation of isobaric compounds, acetic acid at a concentration of 0.2% (*v*/*v*) was selected as the mobile phase additive.

Furthermore, the column temperature was a critical factor that affected the separation of isobaric compounds in this study. Five different temperatures (30, 35, 40, 45, and 50 °C) were tested, and the best separation was achieved at 50 °C. No attempt was made to increase the column temperature above 50 °C as doing so could damage the column. Although some compounds such as tadalafil and xanthoanthrafil did not show baseline separation under the given chromatographic conditions, they could be distinguished by their accurate masses. Accordingly, a temperature of 50 °C was selected for LC--MS analysis. The retention times and mass errors of all analytes are listed in [Table 1](#molecules-25-02734-t001){ref-type="table"}, and the extracted ion chromatograms are depicted in [Figure 1](#molecules-25-02734-f001){ref-type="fig"}.

2.2. Method Validation {#sec2dot2-molecules-25-02734}
----------------------

As the main purpose of this study was qualitative analysis, validation was limited to verification of the method. Nevertheless, quantitative analysis was required in some cases. To improve the quantitative precision and accuracy of our analytical method, phenolphthalein was used as an internal standard (IS).

At a higher concentration, saturation of the IT occurred, and loss of linearity and mass spectral distortion were observed owing to the space charge effect in the IT-type MS \[[@B39-molecules-25-02734]\]. Thus, linearity was estimated over a narrow range. Each calibration curve was constructed with six different concentrations of the 38 PDE-5 inhibitors and their analogs through linear regression analysis. All compounds showed appropriate linearity (*R*^2^ \> 0.99) over the estimated concentration ranges ([Table 2](#molecules-25-02734-t002){ref-type="table"}).

The precision of the method was evaluated in terms of intra- and inter-day precision, estimated by testing a mixed standard solution in five replicates in a day and by repeating the test on five consecutive days. The QC samples were consisted with three different concentrations: Low concentration (L): the lowest concentration in the calibration curve; Medium concentration (M): about 1.67 times higher concentration than low concentration; High concentration (H): the highest concentration in the calibration curve. The intra- and inter-day precision of the 38 PDE-5 inhibitors and their analogs ranged from 0.6% to 9.2% and from 1.2% to 10.5%, respectively. The corresponding intra- and inter-day accuracy ranged from 86.7% to 112.0% and from 89.7% to 105.7%. Based on the results for the validation parameters, this method was demonstrated to be reproducible and reliable for the tested concentration range ([Table 3](#molecules-25-02734-t003){ref-type="table"}).

The reproducibility of the accurate mass measurement of the analytes was evaluated by testing a mixed standard solution in six replicates. The accurate masses, the mass errors to theoretical mass, and standard deviation (SD) values are listed in [Table 4](#molecules-25-02734-t004){ref-type="table"}. The reproducibility of accurate mass measurement ranged from 0.42 to 5.47 as SD, and the mass errors to theoretical mass were less than 10 ppm. As the average mass of carbon varies between 12.0107 and 12.0111 due to variations in the natural abundance of ^13^C, the mass accuracy was limited to 10 ppm \[[@B40-molecules-25-02734]\]. Because the fluctuation of the flight tube temperature could affect the flight distance of the analytes and eventually increase or decrease the mass errors, the temperature of the flight tube in the TOF mass analyzer was kept at 40 °C to maintain the mass accuracy \[[@B41-molecules-25-02734]\]. In addition, the TOF analyzer was calibrated before the analysis using sodium trifluoroacetate solution in accordance with the in-house standard operating procedure.

2.3. MS^n^ Analysis {#sec2dot3-molecules-25-02734}
-------------------

For identification, a tandem MS analysis should be performed for both references and the analytes of interests as it allows for a clear comparison of their spectra. To construct the spectral library, the reference spectra should contain as many fragment ions as possible because they can be used as queries. Therefore, optimization of the collision energy is important to build the spectral library. At low collision energy (\<150% of the relative collision energy), the tandem MS spectra contained only a limited number of fragment ions, such as the dehydrated ("parent ion---18 Da") form of the parent ion. At the relative collision energy of 150%, there were more fragment ions as compared to those formed at a lower collision energy without loss of information of the parent ions. Accordingly, the applied relative collision energy was set to 150%. In addition, as some compounds did not produce identifiable fragment ions in MS^2^ analysis, MS^3^ analysis was performed to obtain more fragment ions for more efficient identification and for effectively building the spectral library. The mass errors, elemental compositions, and accurate masses of the precursors and fragment ions are listed in [Table 4](#molecules-25-02734-t004){ref-type="table"} and [Table S1](#app1-molecules-25-02734){ref-type="app"}. The MS^n^ spectra and proposed fragmentation mechanisms are depicted in [Figure 2](#molecules-25-02734-f002){ref-type="fig"}, [Figure 3](#molecules-25-02734-f003){ref-type="fig"}, [Figure 4](#molecules-25-02734-f004){ref-type="fig"} and [Figure 5](#molecules-25-02734-f005){ref-type="fig"} and [Figures S1--S15](#app1-molecules-25-02734){ref-type="app"}.

### 2.3.1. Sildenafil and Its Derivatives {#sec2dot3dot1-molecules-25-02734}

Representative MS^2^ and MS^3^ spectra, and the proposed fragmentation mechanism of sildenafil and its derivatives are shown in [Figure 2](#molecules-25-02734-f002){ref-type="fig"}. A total of 22 compounds of sildenafil and their derivatives were analyzed. In the CID process, sildenafil and its derivatives showed a common fragmentation mechanism owing to their structural similarity. The exact masses and elemental compositions of the major fragment ions observed in the MS^2^ or MS^3^ spectra were *m*/*z* 312.1573 and *m*/*z* 284.1221, and their elemental compositions were C~17~H~19~N~4~O~2~ and C~15~H~15~N~4~O~2~, respectively ([Table 4](#molecules-25-02734-t004){ref-type="table"} and [Figure 2](#molecules-25-02734-f002){ref-type="fig"}A). The product ion of *m*/*z* 312.1573 was formed by a neutral loss of the sulfonyl group, and the ion of *m*/*z* 284.1221 was produced by a neutral loss of an ethyl moiety (-C~2~H~2~, -28 Da) from the ion of *m*/*z* 312.1573. In addition, product ions of *m*/*z* 311.1456 and *m*/*z* 283.1162 had 1 Da lower mass than that of the major fragment ions. The presence of the two groups of fragment ions indicated that more than one pathway could account for the formation of these fragments. The fragment ion observed at *m*/*z* 312.1573 was produced by the homolytic cleavage of the C-S bond, while the ion of *m*/*z* 311.1456 was formed by inductive cleavage \[[@B42-molecules-25-02734]\]. This fragmentation mechanism was the same as that reported in the literature \[[@B3-molecules-25-02734],[@B11-molecules-25-02734],[@B31-molecules-25-02734],[@B42-molecules-25-02734]\].

In the case of thiosildenafil derivatives ([Figure 2](#molecules-25-02734-f002){ref-type="fig"}B), the proposed fragmentation mechanism was almost the same as that described above; fragment ions of *m*/*z* 328.1344 (C~17~H~19~N~4~OS) and *m*/*z* 300.1022 (C~15~H~15~N~4~OS) were formed by C-S bond cleavage and subsequent detachment of the ethyl moiety. The mass of the fragment ions was 16 Da lower than that of the fragments from sildenafil; this difference was attributable to the presence of the thioketone moiety, whose mass was 16 Da higher than that of the ketone moiety in sildenafil.

Isobaric analytes could be distinguished by their retention times and MS^2^ or MS^3^ spectra. For instance, the theoretical mass and elemental compositions of homosildenafil and dimethylsildenafil were 489.2229 Da and C~23~H~32~N~6~O~4~S, respectively; however, their retention times were different (13.0 and 13.7 min, respectively, [Figure 1](#molecules-25-02734-f001){ref-type="fig"} and [Table 2](#molecules-25-02734-t002){ref-type="table"}). In the MS^2^ spectra of homosildenafil and dimethylsildenafil ([Figure S1](#app1-molecules-25-02734){ref-type="app"}), the ion of *m*/*z* 312 was observed as a base peak, and the ion of *m*/*z* 284 was the second most intense peak. The ion ratio of *m*/*z* 284.1230 to *m*/*z* 312.1542 in the MS^2^ spectrum of homosildenafil was about three times higher than that in the spectrum of dimethylsildenafil. Thiohomosildenafil and dimethylthiosildenafil were separately observed at retention times of 24.1 and 25.1 min ([Table 2](#molecules-25-02734-t002){ref-type="table"}), and their elemental composition was C~23~H~32~N~6~O~3~S~2~. Their MS^2^ and MS^3^ spectra were almost the same, except for their different *m*/*z* 300.1012 to *m*/*z* 328.1332 ion ratios ([Figure S2](#app1-molecules-25-02734){ref-type="app"}). In the MS^2^ spectrum of thiohomosildenafil, the ion ratio of *m*/*z* 300.1019 to *m*/*z* 328.1364 was approximately three times higher than that in the MS^2^ spectrum of dimethylthiosildenafil. These results indicate that both the separation capability and the ion ratio of certain fragment ions in tandem MS spectra were important to gain sufficient information for discriminating the isobaric compounds.

### 2.3.2. Vardenafil and Its Derivatives {#sec2dot3dot2-molecules-25-02734}

Representative MS^2^ and MS^3^ spectra and the proposed fragmentation mechanism of vardenafil are shown in [Figure 3](#molecules-25-02734-f003){ref-type="fig"}A. The structures of vardenafil and its derivatives were almost identical to those of sildenafil and its derivatives. In the CID spectra of vardenafil and its derivatives, the fragment ions of *m*/*z* 312.1555 (C~17~H~19~N~4~O~2~) and *m*/*z* 284.1253 (C~15~H~15~N~4~O~2~) were formed by the fragmentation mechanisms identical to those for sildenafil and its derivatives owing to their structural similarity. However, the ions produced by the homolytic cleavage of the C-S bond were not found in the MS^n^ spectra of vardenafil, and the ion of *m*/*z* 151.0877 (C~8~H~10~N~2~O), which was formed by the cross ring cleavage of triazin-4-one, was observed only in the CID process of vardenafil and its derivatives.

Because of the structural similarity between the vardenafil and sildenafil derivatives, the fragment ions generated in the MS^2^ or MS^3^ spectra were almost same. For example, when comparing the MS^2^ spectra of the vardenafil and sildenafil derivatives with the same molecular weights, such as homosildenafil and dimethylsildenafil, the major fragment ions were observed at *m*/*z* 312.1555 and *m*/*z* 284.1253. The ratio of these ions in the MS^2^ spectrum of vardenafil was similar to that in the spectrum of homosildenafil. Therefore, it was difficult to distinguish between vardenafil and homosildenafil by their MS^2^ spectra on the basis of the major fragment ions and the ion ratio of a certain fragment ion. As previously described in this section, the ion of *m*/*z* 151.0877 (C~8~H~10~N~2~O), a diagnostic ion of vardenafil, was only found in the MS^2^ or MS^3^ spectra of vardenafil analogs. Thus, we could distinguish vardenafil analogs from those of sildenafil by simply observing the diagnostic ion in the MS^2^ or MS^3^ spectra of the analytes.

### 2.3.3. Tadalafil and Its Derivatives {#sec2dot3dot3-molecules-25-02734}

Representative MS^2^ and MS^3^ spectra and the proposed fragmentation mechanism of tadalafil are depicted in [Figure 3](#molecules-25-02734-f003){ref-type="fig"}B. In the CID spectra of tadalafil, the ion observed at *m*/*z* 268.1050 (C~15~H~13~N~3~O~2~) was formed by a neutral loss of 1,3-benzodioxole, and the ion of *m*/*z* 240.1099 (C~14~H~13~N~3~O) was produced by the loss of the carbonyl (CO) group from the ion with *m*/*z* 268.1050. The ion of *m*/*z* 197.0707 (C~12~H~8~N~2~O) was formed by a neutral loss of 1,3-benzodioxole and the cross ring cleavage of piperazine-2,5-dione, and the ion of *m*/*z* 169.0736 (C~11~H~8~N~2~) was produced by the loss of a CO group from the ion of *m*/*z* 197.0707. The ion observed at *m*/*z* 262.0866 was formed by a neutral loss of piperazine-2,5-dione. The fragment ions of *m*/*z* 262.0866, *m*/*z* 197.0707, and *m*/*z* 169.0736 and a neutral loss of 1,3-benzodioxole are commonly observed in the CID spectra of tadalafil derivatives.

### 2.3.4. Other Classes {#sec2dot3dot4-molecules-25-02734}

The CID spectra of mirodenafil, xanthoanthrafil, thioquinapiperifil, and yohimbine are shown in [Figure 4](#molecules-25-02734-f004){ref-type="fig"}; [Figure 5](#molecules-25-02734-f005){ref-type="fig"}. As the structure of mirodenafil was almost the same as that of sildenafil, its fragment ions were produced by the same fragmentation mechanism as that of sildenafil ([Figure 4](#molecules-25-02734-f004){ref-type="fig"}A). The ion observed at *m*/*z* 339.1914 (C~20~H~24~N~3~O~2~) was formed by the cleavage of the C-S bond, and the ion of *m*/*z* 297.1444 (C~17~H~18~N~3~O~2~) was produced by a neutral loss of the propyl group of phenyl propyl ether. The doubly charged ion of *m*/*z* 245.6061 (C~23~H~31~N~5~O~5~S) was formed by a neutral loss of the propyl group of phenyl propyl ether, and the ion of *m*/*z* 236.6006 (C~23~H~29~N~5~O~4~S) was produced by intra-molecular dehydration (-H~2~O) from the ion of *m*/*z* 245.6061.

The structures of xanthoanthrafil and thioquinapiperifil were different from those of other PDE-5 inhibitors and their analogs. As they have unique structures, the fragment ions produced in the CID spectra were different from those of other classes of analytes.

In the MS^2^ spectra of xanthoanthrafil ([Figure 4](#molecules-25-02734-f004){ref-type="fig"}B), the fragment ion of *m*/*z* 151.0740 (C~9~H~10~O~2~) was predominant. The ion observed at *m*/*z* 151.0740 was formed by a neutral loss of the 3-nitrobenzamide group. The ions of *m*/*z* 344.1670 (C~19~H~23~N~2~O~4~) and *m*/*z* 268.1049 (C~16~H~14~NO~3~) were produced by a sequential neutral loss of the NO~2~ group.

The fragment ions of thioquinapiperifil in the MS^2^ spectra ([Figure 5](#molecules-25-02734-f005){ref-type="fig"}A) were observed at *m*/*z* 246.0774 (C~11~H~11~N~5~S), *m*/*z* 204.1343 (C~13~H~17~NO), *m*/*z* 218.0493 (C~9~H~7~N~5~S), and *m*/*z* 189.0773 (C~20~H~20~N~6~S). The fragment ion of *m*/*z* 204.1343 was formed by the loss of the quinazolin-4-amine moiety, and that of *m*/*z* 246.0774 was produced by cleavage between quinazolin-4-amine and the benzyl group. The fragment ion of *m*/*z* 218.0493 was formed by a neutral loss of the ethyl moiety from the ion of *m*/*z* 246.0774, and the product ion of *m*/*z* 189.0773, a doubly charged ion, was produced by the cross ring cleavage of the piperidine ring.

The major product ions in the MS^2^ spectra of yohimbine ([Figure 5](#molecules-25-02734-f005){ref-type="fig"}B) were observed at *m*/*z* 212.1248 (C~11~H~17~NO~3~) and *m*/*z* 144.0803 (C~10~H~9~N), which were formed by piperidine ring cleavage. The MS^3^ spectra of the ion of *m*/*z* 212.1248 gave ions of *m*/*z* 194.1150 (C~11~H~15~NO~2~), *m*/*z* 180.1015 (C~10~H~13~NO~2~), *m*/*z* 162.0900 (C~10~H~11~NO), *m*/*z* 152.1059 (C~9~H~13~NO), and *m*/*z* 134.0955 (C~9~H~11~N). The ion observed at *m*/*z* 194.1150 was formed by intra-molecular dehydration from the aliphatic hydroxyl (-OH) group. The ions of *m*/*z* 180.1015 and *m*/*z* 152.1059 were formed by the loss of an ester moiety, and the ions of *m*/*z* 162.0900 and *m*/*z* 134.0955 were produced by intra-molecular dehydration (loss of the aliphatic hydroxyl group) from ions of *m*/*z* 180.1015 and *m*/*z* 152.1059, respectively. These ions were confirmed by measuring their accurate mass and elemental composition. The high-resolution MS^n^ spectral library was built using all MS^n^ spectra acquired from this study; all details are provided in the [Supplementary Materials (Figures S1--S15 and Table S1)](#app1-molecules-25-02734){ref-type="app"}.

2.4. Analysis of Real Samples {#sec2dot4-molecules-25-02734}
-----------------------------

Two positive samples (denoted as sample 1 and sample 2) were analyzed by the developed LC--MS method. The samples were extracted with methanol and diluted 1000-fold with 50% methanol. Their total ion chromatograms, MS^n^ (*n* = 1--3) spectra, and library search results are depicted in [Figure 6](#molecules-25-02734-f006){ref-type="fig"}. As shown in [Figure 6](#molecules-25-02734-f006){ref-type="fig"}, the unknown peaks were detected as the major peak even in the 1000-fold diluted samples. Two additional peaks were also observed in both samples. These peaks might be derived from the dilution solvent (50% methanol) or sample container because they appeared when the dilution solvent alone (present in the sample container) was injected into the LC--MS system (data not shown).

The unknown peak of sample 1 was observed at the retention time of 14.3 min with an accurate mass of *m*/*z* 245.1151 (\[M + 2H\]^2+^; [Figure 6](#molecules-25-02734-f006){ref-type="fig"}A). According to the accurate mass, the possible candidates for the unknown compound were homosildenafil, dimethylsildenafil, and vardenafil with mass errors of 10.2 ppm. On comparing the retention times of these candidates, the retention time of dimethylsildenafil was found to be similar to that of the unknown peak. Further confirmation was achieved by retrieving the MS^n^ spectral library. The library provided three matched candidates with similarity scores of over 92, namely, dimethylsildenafil, vardenafil, and sildenafil. Vardenafil was excluded from the consideration because the tandem MS spectra did not contain the diagnostic fragment ion (*m*/*z* 151.0866, C~8~H~10~N~2~O) of vardenafil. Sildenafil was also excluded because the molecular weight of the unknown was completely different from that of sildenafil. These clues collectively suggested with a high confidence level that the unknown peak belongs to dimethylsildenafil.

In the chromatogram of sample 2, the unknown peak was observed at the retention time of 13.2 min with an accurate mass of *m*/*z* 475.2093 (\[M + H\]^+^; [Figure 6](#molecules-25-02734-f006){ref-type="fig"}B). By considering the retention time and accurate mass, a possible candidate was sildenafil with a mass error of 6.1 ppm. The spectral library suggested two possible candidates with a similarity score of over 91, namely, sildenafil and dimethylsildenafil. As the molecular weight of the unknown peak only matched with sildenafil among the two candidates with a high confidence level, it was concluded that this unknown peak was sildenafil.

3. Materials and Methods {#sec3-molecules-25-02734}
========================

3.1. Chemicals and Reagents {#sec3dot1-molecules-25-02734}
---------------------------

Thirty-eight standards of PDE-5 inhibitors and their analogs were obtained from Seoul Regional Ministry of Food and Drug Safety (MFDS, Seoul, Republic of Korea). The PDE-5 inhibitors and their analogs included sildenafil, vardenafil, tadalafil, mirodenafil, udenafil, thioquinapiperifil, hydroxyvardenafil, hydroxyhongdenafil, hongdenafil, piperidinohongdenafil, dimethylsildenafil, cyclopentinafil, benzylsildenafil, thiosildenafil, dimethylthiosildenafil, chloropretadalafil, nitrodenafil, nor-neosildenafil, hydroxyhomosildenafil, acetylvardenafil, nor-neovardenafil, desulfovardenafil, aminotadalafil, yohimbine, demethylhongdenafil, oxohongdenafil, homosildenafil, xanthoanthrafil, pseudovardenafil, hydroxychlorodenafil, chlorodenafil, *N*-octyltadalafil, dichlorodenafil, carbodenafil, thiohomosildenafil, hydroxythiohomosildenafil, acetaminotadalafil, and demethyltadalafil. Phenolphthalein (internal standard, IS) was purchased from Sigma Aldrich (St. Louis, MO, USA). The detailed structures of the analytes were depicted in the [Table S2](#app1-molecules-25-02734){ref-type="app"}. HPLC-grade methanol, acetonitrile, and water were purchased from Thermo Fisher Scientific (Fair Lawn, NJ, USA). Glacial acetic acid (99.7%), formic acid (98%), and ammonium formate were purchased from Sigma Aldrich. Stock solutions of the standards were dissolved in methanol at the appropriate concentration and stored in the refrigerator (4 °C). All standard solutions were mixed and diluted to appropriate concentration with 50% methanol.

3.2. Sample Preparation {#sec3dot2-molecules-25-02734}
-----------------------

Dietary supplements (100 mg) suspected of adulteration with PDE-5 inhibitor analogs were vortexed for 10 min with 10 mL of methanol and extracted in an ultrasonic bath for 30 min at room temperature.

After extraction, the samples were centrifuged at 3500 rpm for 10 min. The supernatants were filtered through a syringe filter (0.45 μm of pore size). The aliquot of the filtered supernatants was diluted with 50% methanol by a dilution factor of 100 or 1000.

3.3. Instrumentation and Separation Conditions {#sec3dot3-molecules-25-02734}
----------------------------------------------

The LC--MS/MS system consisted of a Shimadzu LC-20A HPLC system and LC--IT--TOF MS equipped with an electrospray ionization source (Shimadzu, Kyoto, Japan). The chromatographic separation was achieved on the Capcell PAK C18 UG120 column (2.1 × 150 mm, 3 μm particle size, Shiseido, Tokyo, Japan) using a mobile phase comprising 0.2% acetic acid (A) and acetonitrile (B) at a flow rate of 0.2 mL/min and a temperature of 50 °C. The gradient program was as follows: 0 min, 10% B; 5 min, 20% B; 45 min, 40% B; 50 min, 85% B; 55 min, 85% B; 55.1 min, 10% B; 70 min, 10% B. The injection volume was 5 μL. The operating electrospray ionization (ESI) parameters were as follows: ion spray voltage, 4.5 kV; drying gas (N~2~), 1.5 L/min; and curved desolvation line temperature and heat block temperature, 200 °C. The MS system was calibrated prior to the analysis by using sodium trifluoroacetate solution. The HPLC and MS systems were controlled by the Lab Solution (Ver. 3.1.360) software.

3.4. MS^n^ Analysis {#sec3dot4-molecules-25-02734}
-------------------

Data-dependent MS^n^ (*n* = 1--3) analysis was adopted to obtain structural information of the analytes. The precursor ion was selected over the range of *m*/*z* 100--800, and the MS^n^ spectra were obtained at the relative collision energy of 150%. Three precursor ions were selected automatically in the order of their intensity in a given spectrum (over 100,000 cps). Ion accumulation time in the ion trap was set to 10 ms for both MS and MS^n^ (*n* = 2, 3) modes. Elemental composition and mass error were calculated using accurate mass by the formula predictor software included in the Lab Solution software. The spectral libraries of the references were built on the basis of the MS^2^ and MS^3^ spectra by the library editor software included in the Lab Solution software.

3.5. Method Validation {#sec3dot5-molecules-25-02734}
----------------------

Calibration curves for LC--MS were constructed with six different concentration levels from the concentration ranges listed in [Table 1](#molecules-25-02734-t001){ref-type="table"}. The intra- and inter-day precision (CV) and accuracy (%) were estimated by analyzing five replicates at three different concentrations all within one day or over five days. The reproducibility of accurate mass measurements was estimated by analyzing six replicates.

4. Conclusions {#sec4-molecules-25-02734}
==============

An accurate screening method for PDE-5 inhibitors and their analogs in dietary supplements was developed using hybrid IT--TOF MS and validated. IT--TOF MS gave more accurate information on the structure of analytes by providing accurate masses of the parent ion as well as fragment ions, which could be converted to determine elemental composition. The spectral library of references was built against the MS^n^ spectra for retrieving the structural hits. The library suggested appropriate candidates and helped identify the unknown compounds during the real sample analysis. The combined measurement of accurate mass and retention time of the analytes facilitated accurate identification of the adulterated compounds. In conclusion, the developed LC--MS method and MS^n^ spectral library provided spectral insights for newly synthesized PDE-5 inhibitors and facilitated the rapid screening and identification of illegally adulterated analogs.

**Sample Availability:** Samples of the compounds are not available from the authors.

The following are available online, Figure S1: Representative MS^n^ (*n* = 2, 3) spectra and proposed fragmentation mechanisms of homosildenafil (**A**) and dimethylsildenafil (**B**). The bracketed numbers next to the *m*/*z* values indicate the charge state of the ions; Figure S2: Representative MS^n^ (*n* = 2, 3) spectra and proposed fragmentation mechanisms of thiohomosildenafil (**A**) and dimethylthiosildenafil (**B**). The bracketed numbers next to the *m*/*z* values indicate the charge state of the ions; Figure S3: Representative MS^n^ (*n* = 2, 3) spectra and proposed fragmentation mechanisms of benzylsildenafil (**A**) and carbodenafil (**B**). The bracketed numbers next to the *m*/*z* values indicate the charge state of the ions; Figure S4: Representative MS^n^ (*n* = 2, 3) spectra and proposed fragmentation mechanisms of nor-neosildenafil (**A**) and cyclopentinafil (**B**). The bracketed numbers next to the *m*/*z* values indicate the charge state of the ions; Figure S5: Representative MS^2^ spectra and proposed fragmentation mechanisms of hydroxythiohomosildenafil (**A**) and hydroxyhomosildenafil (**B**). The bracketed numbers next to the *m*/*z* values indicate the charge state of the ions; Figure S6: Representative MS^n^ (*n* = 2, 3) spectra and proposed fragmentation mechanisms of chlorodenafil (**A**) and dichlorodenafil (**B**). The bracketed numbers next to the *m*/*z* values indicate the charge state of the ions; Figure S7: Representative MS^2^ spectra and proposed fragmentation mechanisms of hydroxychlorodenafil (**A**) and nitrodenafil (**B**). The bracketed numbers next to the *m*/*z* values indicate the charge state of the ions; Figure S8: Representative MS^n^ (*n* = 2, 3) spectra and proposed fragmentation mechanisms of udenafil (**A**) and hongdenafil (**B**). The bracketed numbers next to the *m*/*z* values indicate the charge state of the ions; Figure S9: Representative MS^2^ and proposed fragmentation mechanisms of piperidinohongdenafil (**A**) and demethylhongdenafil (**B**). The bracketed numbers next to the *m*/*z* values indicate the charge state of the ions; Figure S10: Representative MS^2^ spectra and proposed fragmentation mechanisms of hydroxyhongdenafil (**A**) and oxohongdenafil (**B**). The bracketed numbers next to the *m*/*z* values indicate the charge state of the ions; Figure S11: Representative MS^2^ spectra and proposed fragmentation mechanisms of desolfovardenafil (**A**) and nor-neovardenafil (**B**). The bracketed numbers next to the *m*/*z* values indicate the charge state of the ions; Figure S12: Representative MS^2^ spectra and proposed fragmentation mechanisms of pseudovardenafil (**A**) and acetylvardenafil (**B**). The bracketed numbers next to the *m*/*z* values indicate the charge state of the ions; Figure S13: Representative MS^2^ spectra and proposed fragmentation mechanisms of hydroxyvardenafil (**A**) and acetaminotadalafil (**B**). The bracketed numbers next to the *m*/*z* values indicate the charge state of the ions; Figure S14: Representative MS^2^ spectra and proposed fragmentation mechanisms of aminotadalafil (**A**) and demethyltadalafil (**B**). The bracketed numbers next to the *m*/*z* values indicate the charge state of the ions; Figure S15: Representative MS^n^ (*n* = 2, 3) spectra and proposed fragmentation mechanisms of chloropretadalafil (**A**) and *N*-octyltadalafil (**B**). The bracketed numbers next to the *m*/*z* values indicate the charge state of the ions; Table S1: Accurate masses and mass errors for fragment and precursor ions of PDE-5 inhibitors and their analogs; Table S2: The structures of PDE-5 inhibitors and their analogues.

###### 
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![Extracted ion chromatograms of PDE-5 inhibitors and their analogs: Sildenafil (**1**), carbodenafil (**2**), demethylhongdenafil (**3**), hydroxyhongdenafil (**4**), hongdenafil (**5**), hydroxyhomosildenafil (**6**), piperidinohongdenafil (**7**), homosildenafil (**8**), dimethylsildenafil (**9**), udenafil (**10**), cyclopentinafil (**11**), thiosildenafil (**12**), hydroxythiohomosildenafil (**13**), thiohomosildenafil (**14**), dimethylthiosildenafil (**15**), oxohongdenafil (**16**), benzylsildenafil (**17**), hydroxychlorodenafil (**18**), chlorodenafil (**19**), nitrodenafil (**20**), nor-neosildenafil (**21**), dichlorodenafil (**22**), vardenafil (**23**), acetylvardenafil (**24**), hydroxyvardenafil (**25**), nor-neovardenafil (**26**), desulfovardenafil (**27**), pseudovardenafil (**28**), tadalafil (**29**), aminotadalafil (**30**), acetaminotadalafil (**31**), demethyltadalafil (**32**), chloropretadalafil (**33**), *N*-octyltadalafil (**34**), yohimbine (**35**), mirodenafil (**36**), thioquinapiperifil (**37**), xanthoanthrafil (**38**), and phenolphthalein (**39**). \* indicated the analytes among multiple peaks in the EIC.](molecules-25-02734-g001){#molecules-25-02734-f001}

![Representative MS^n^ (*n* = 2, 3) spectra and proposed fragmentation mechanisms of sildenafil (**A**) and thiosildenafil (**B**). The bracketed numbers next to the *m*/*z* values indicate the charge state of the ions.](molecules-25-02734-g002){#molecules-25-02734-f002}

![Representative MS^n^ (*n* = 2, 3) spectra and proposed fragmentation mechanisms of vardenafil (**A**) and tadalafil (**B**). The bracketed numbers next to the *m*/*z* values indicate the charge state of the ions.](molecules-25-02734-g003){#molecules-25-02734-f003}

![Representative MS^n^ (*n* = 2, 3) spectra and proposed fragmentation mechanisms of mirodenafil (**A**) and xanthoanthrafil (**B**). The bracketed numbers next to the *m*/*z* values indicate the charge state of the ions.](molecules-25-02734-g004){#molecules-25-02734-f004}

![Representative MS^n^ (*n* = 2, 3) spectra and proposed fragmentation mechanisms of thioquinapiperifil (**A**) and yohimbine (**B**). The bracketed numbers next to the *m*/*z* values indicate the charge state of the ions.](molecules-25-02734-g005){#molecules-25-02734-f005}

![MS^n^ (*n* = 2, 3) spectra, total ion chromatograms, and library search results for real samples. (**A**) MS^2^ and MS^3^ spectra of sample 1, (**B**) chromatogram and corresponding MS spectrum of sample 1, (**C**) library search result for sample 1, (**D**) MS^2^ and MS^3^ spectra of sample 2, (**E**) chromatogram and corresponding MS spectrum of sample 2, and (**F**) library search result for sample 2.](molecules-25-02734-g006){#molecules-25-02734-f006}

molecules-25-02734-t001_Table 1

###### 

Retention times and mass errors of PDE-5 inhibitors and their analogs.

  ----------------------------------------------------------------------------------------------------------------------------------------
  Compound                    Retention Time (min)   Elemental Composition     Measured Mass   Theoretical Mass   ∆*m*\   Mass Error\
                                                                                                                  (mDa)   (ppm ± SD ^a^)
  --------------------------- ---------------------- ------------------------- --------------- ------------------ ------- ----------------
  Sildenafil                  12.6                   C~22~H~30~N~6~O~4~S       475.2125        475.2122           0.30    0.63 ± 2.21

  Carbodenafil                9.3                    C~24~H~32~N~6~O~3~        453.2599        453.2609           −1.02   −2.26 ± 0.54

  Demethylhongdenafil         9.3                    C~24~H~32~N~6~O~3~        453.2618        453.2609           0.94    2.08 ± 3.68

  Hydroxyhongdenafil          9.9                    C~25~H~34~N~6~O~4~        483.2728        483.2714           1.41    2.91 ± 1.70

  Hongdenafil                 10.6                   C~25~H~34~N~6~O~3~        467.2753        467.2765           −1.19   −2.55 ± 3.09

  Hydroxyhomosildenafil       10.9                   C~23~H~32~N~6~O~5~S       505.2215        505.2228           −1.26   −2.49 ± 2.36

  Piperidinohongdenafil       11.2                   C~24~H~31~N~5~O~3~        438.2505        438.2500           0.48    1.10 ± 1.47

  Homosildenafil              13.0                   C~23~H~32~N~6~O~4~S       489.2278        489.2279           −0.06   −0.12 ± 0.42

  Dimethylsildenafil          13.7                   C~23~H~32~N~6~O~4~S       489.2291        489.2279           1.24    2.54 ± 0.95

  Udenafil                    15.0                   C~25~H~36~N~6~O~4~S       517.2567        517.2592           −2.52   −4.48 ± 0.63

  Cyclopentinafil             16.2                   C~26~H~36~N~6~O~4~S       529.2591        529.2592           −0.09   −0.17 ± 0.52

  Thiosildenafil              23.6                   C~22~H~30~N~6~O~3~S~2~    491.1882        491.1893           −1.09   −2.22 ± 0.94

  Hydroxythiohomosildenafil   23.7                   C~23~H~32~N~6~O~4~S~2~    521.1956        521.1999           −4.32   −8.30 ± 2.15

  Thiohomosildenafil          24.4                   C~23~H~32~N~6~O~3~S~2~    505.2013        505.2050           −3.73   −7.37 ± 2.56

  Dimethylthiosildenafil      25.1                   C~23~H~32~N~6~O~3~S~2~    505.2018        505.2050           −3.23   −6.38 ± 2.42

  Oxohongdenafil              28.9                   C~25~H~32~N~6~O~4~        481.2569        481.2558           1.11    2.30 ± 1.22

  Benzylsildenafil            30.6                   C~28~H~34~N~6~O~4~S       551.2403        551.2435           −3.19   −5.79 ± 1.20

  Hydroxychlorodenafil        40.5                   C~19~H~23~N~4~O~3~Cl      391.1528        391.1531           −0.28   −0.72 ± 1.60

  Chlorodenafil               48.4                   C~19~H~21~N~4~O~3~Cl      389.1377        389.1375           0.17    0.43 ± 1.10

  Nitrodenafil                49.6                   C~17~H~19~N~5~O~4~        358.1512        358.1510           0.17    0.47 ± 1.59

  Nor-neosildenafil           51.7                   C~22~H~29~N~5~O~4~S       460.2014        460.2013           0.08    0.18 ± 1.72

  Dichlorodenafil             53.6                   C~19~H~20~N~4~O~2~Cl~2~   407.1038        407.1036           0.20    0.49 ± 1.81

  Vardenafil                  11.1                   C~23~H~32~N~6~O~4~S       489.2296        489.2279           1.67    3.42 ± 0.86

  Acetylvardenafil            9.3                    C~25~H~34~N~6~O~3~        467.2758        467.2765           −0.69   −1.48 ± 5.47

  Hydroxyvardenafil           10.9                   C~23~H~32~N~6~O~5~S       505.2209        505.2228           −1.86   −3.68 ± 0.84

  Nor-neovardenafil           23.9                   C~18~H~20~N~4~O~4~        357.1557        357.1557           −0.02   −0.05 ± 0.86

  Desulfovardenafil           37.1                   C~17~H~20~N~4~O~2~        313.1651        313.1659           −0.80   −2.55 ± 0.88

  Pseudovardenafil            48.5                   C~22~H~29~N~5~O~4~S       460.2013        460.2013           −0.05   −0.11 ± 0.64

  Tadalafil                   29.8                   C~22~H~19~N~3~O~4~        390.1449        390.1448           0.10    0.26 ± 1.42

  Aminotadalafil              24.4                   C~21~H~18~N~4~O~4~        391.1410        391.1401           0.88    2.26 ± 1.57

  Acetaminotadalafil          24.6                   C~23~H~20~N~4~O~5~        433.1502        433.1506           −0.42   −0.96 ± 1.81

  Demethyltadalafil           25.5                   C~21~H~17~N~3~O~4~        376.1293        376.1292           0.07    0.18 ± 1.36

  Chloropretadalafil          48.5                   C~22~H~19~N~2~O~5~Cl      427.1031        427.1055           −2.42   −5.66 ± 1.62

  *N*-Octyltadalafil          53.1                   C~29~H~33~N~3~O~4~        488.2559        488.2544           1.48    3.04 ± 3.23

  Yohimbine                   6.4                    C~21~H~26~N~2~O~3~        532.2580        532.2588           −0.82   −1.55 ± 0.97

  Mirodenafil                 22.4                   C~26~H~37~N~5~O~5~S       355.2012        355.2016           −0.43   −1.22 ± 1.73

  Thioquinapiperifil          10.8                   C~24~H~28~N~6~OS          449.2098        449.2118           −1.96   −4.36 ± 2.06

  Xanthoanthrafil             30.2                   C~19~H~23~N~3~O~6~        390.1660        390.1660           −0.02   −0.04 ± 1.94

  IS ^b^ (Phenolphthalein)    27.7                   C~20~H~14~O~4~            319.0934        319.0965           −3.10   9.72
  ----------------------------------------------------------------------------------------------------------------------------------------

^a^ Standard deviation; ^b^ Internal standard.

molecules-25-02734-t002_Table 2

###### 

Linear regression equations and linear correlation coefficients of PDE-5 inhibitors and their analogs.

  Compound                    Equation                  Range (μg/mL)   *R* ^2^
  --------------------------- ------------------------- --------------- ---------
  Sildenafil                  *y* = 0.169 *x* + 0.006   0.30--0.80      0.993
  Carbodenafil                *y* = 0.430 *x* − 0.008   0.16--0.43      0.997
  Hongdenafil                 *y* = 0.783 *x* + 0.037   0.38--1.00      0.997
  Hydroxyhongdenafil          *y* = 0.506 *x* + 0.170   0.30--0.80      0.994
  Demethylhongdenafil         *y* = 0.403 *x* + 0.020   0.32--0.85      0.996
  Piperidinohongdenafil       *y* = 0.504 *x* + 0.052   0.28--0.74      0.996
  Hydroxyhomosildenafil       *y* = 0.490 *x* + 0.074   0.74--1.98      0.994
  Homosildenafil              *y* = 0.321 *x* + 0.025   0.20--0.55      0.998
  Dimethylsildenafil          *y* = 0.409 *x* + 0.030   0.30--0.80      0.995
  Udenafil                    *y* = 0.504 *x* + 0.133   0.30--0.80      0.999
  Cyclopentinafil             *y* = 0.389 *x* + 0.040   0.30--0.80      0.997
  Thiosildenafil              *y* = 0.165 *x* + 0.026   1.20--3.20      0.996
  Hydroxythiohomosildenafil   *y* = 0.198 *x* + 0.003   0.75--2.00      0.998
  Thiohomosildenafil          *y* = 0.252 *x* + 0.007   0.15--0.40      0.993
  Dimethylthiosildenafil      *y* = 0.255 *x* − 0.010   0.18--0.47      0.995
  Oxohongdenafil              *y* = 0.237 *x* + 0.034   0.60--1.60      0.993
  Benzylsildenafil            *y* = 0.157 *x* + 0.010   0.31--0.84      0.993
  Hydroxychlorodenafil        *y* = 0.302 *x* + 0.011   0.25--0.66      0.998
  Chlorodenafil               *y* = 0.341 *x* + 0.386   1.50--4.00      0.990
  Nitrodenafil                *y* = 0.444 *x* + 0.016   0.15--0.40      0.994
  Nor-neosildenafil           *y* = 0.356 *x* + 0.020   0.20--0.54      0.993
  Dichlorodenafil             *y* = 0.107 *x* + 0.017   0.38--1.00      0.992
  Vardenafil                  *y* = 0.381 *x* + 0.014   0.15--0.40      0.999
  Acetylvardenafil            *y* = 0.501 *x* + 0.046   0.31--0.83      0.992
  Hydroxyvardenafil           *y* = 0.610 *x* + 0.055   0.75--2.00      0.998
  Nor-neovardenafil           *y* = 0.729 *x* + 0.027   0.17--0.45      0.993
  Desulfovardenafil           *y* = 1.289 *x* + 0.052   0.15--0.40      0.991
  Pseudovardenafil            *y* = 0.912 *x* + 0.045   0.15--0.40      0.992
  Tadalafil                   *y* = 0.090 *x* + 0.015   0.70--1.87      0.997
  Aminotadalafil              *y* = 0.048 *x* + 0.018   1.20--3.20      0.997
  Acetaminotadalafil          *y* = 0.108 *x* + 0.022   0.38--1.00      0.990
  Demethyltadalafil           *y* = 0.088 *x* + 0.015   0.75--2.00      0.993
  Chloropretadalafil          *y* = 0.027 *x* + 0.044   1.20--3.20      0.992
  *N*-Octyltadalafil          *y* = 0.043 *x* + 0.019   0.75--2.00      0.996
  Yohimbine                   *y* = 0.539 *x* + 0.028   0.13--0.34      0.995
  Mirodenafil                 *y* = 0.939 *x* + 0.004   0.17--0.45      0.991
  Thioquinapiperifil          *y* = 0.198 *x* − 0.016   0.15--0.40      0.994
  Xanthoanthrafil             *y* = 0.176 *x* + 0.020   0.60--1.60      0.992

molecules-25-02734-t003_Table 3

###### 

Intra- and inter-day accuracy and precision of PDE-5 inhibitors and their analogs.

  Compound                    Intra-Day (*n* = 5)   Inter-Day (*n* = 5)                                                                  
  --------------------------- --------------------- --------------------- ------- ----- ----- ----- ------- ------- ------- ------ ----- -----
  Sildenafil                  104.2                 103.7                 101.6   5.5   3.1   3.9   99.6    103.4   100.1   2.8    3.6   1.9
  Carbodenafil                103.7                 101.6                 99.7    4.8   2.5   5.2   100.9   101.7   96.8    4.4    5.1   4.8
  Hongdenafil                 106.0                 103.8                 99.2    4.0   3.4   3.1   97.1    103.2   98.9    5.9    4.3   4.1
  Hydroxyhongdenafil          101.2                 98.6                  97.6    4.2   2.2   2.0   94.1    98.4    98.2    5.3    3.3   2.0
  Demethylhongdenafil         102.4                 99.6                  98.7    5.2   2.3   5.5   94.4    99.5    96.9    4.2    3.9   2.5
  Piperidinohongdenafil       104.0                 103.4                 96.7    7.1   2.8   2.8   93.0    102.0   97.6    5.3    4.4   1.8
  Hydroxyhomosildenafil       107.1                 104.7                 101.8   6.7   0.7   3.4   94.5    99.9    98.3    5.3    5.3   3.5
  Homosildenafil              102.5                 103.6                 102.1   4.3   3.1   2.9   94.5    105.1   97.8    3.7    2.1   3.3
  Dimethylsildenafil          105.6                 104.7                 102.0   7.8   1.1   1.7   96.0    101.1   100.0   1.2    3.3   3.3
  Udenafil                    98.9                  104.7                 104.7   3.3   3.0   1.4   93.8    103.6   100.7   6.5    2.2   6.1
  Cyclopentinafil             100.2                 100.9                 102.2   4.1   1.5   2.3   95.4    102.7   98.7    5.4    6.1   3.2
  Thiosildenafil              105.3                 105.2                 104.3   7.5   2.8   2.7   93.3    100.6   102.2   4.9    7.3   2.0
  Hydroxythiohomosildenafil   102.9                 104.2                 102.5   5.2   2.5   2.7   97.1    104.4   101.9   4.6    1.6   5.4
  Thiohomosildenafil          103.9                 103.7                 101.4   9.2   4.0   4.0   96.0    99.0    97.8    7.9    4.9   6.3
  Dimethylthiosildenafil      99.5                  96.5                  99.9    3.7   6.7   7.6   96.2    101.2   97.0    8.4    6.8   6.1
  Oxohongdenafil              98.0                  101.8                 99.9    2.3   2.1   2.4   91.3    100.4   99.6    4.0    3.4   1.4
  Benzylsildenafil            96.2                  96.6                  99.3    3.1   3.5   5.6   91.8    99.7    97.7    4.3    3.4   3.2
  Hydroxychlorodenafil        92.5                  98.1                  100.1   1.4   2.2   3.1   91.1    99.1    97.3    3.1    3.7   2.7
  Chlorodenafil               97.0                  103.3                 102.2   4.6   4.5   1.9   89.7    103.0   97.8    7.8    4.2   3.4
  Nitrodenafil                98.3                  99.8                  102.9   3.7   3.0   4.2   89.7    101.0   100.6   9.3    5.7   3.3
  Nor-neosildenafil           105.1                 105.3                 100.0   6.5   1.4   2.9   92.3    102.3   97.4    3.0    3.2   1.9
  Dichlorodenafil             93.5                  100.7                 101.5   2.6   6.2   4.8   90.9    103.4   97.8    4.1    6.3   3.4
  Vardenafil                  100.8                 98.7                  96.4    4.4   3.0   3.7   93.0    100.4   95.8    4.7    4.4   2.9
  Acetylvardenafil            102.1                 103.0                 99.7    5.0   4.7   3.5   96.0    103.6   101.0   4.1    2.9   5.2
  Hydroxyvardenafil           104.9                 102.6                 98.7    5.8   1.9   3.1   96.6    100.6   97.9    5.9    5.3   2.1
  Nor-neovardenafil           87.8                  96.6                  98.1    5.9   3.6   1.3   97.0    103.1   97.7    8.7    5.9   1.6
  Desulfovardenafil           86.7                  94.7                  96.5    5.2   3.3   2.6   91.1    100.9   97.4    3.2    5.4   1.8
  Pseudovardenafil            101.0                 101.2                 100.5   3.0   1.2   2.8   91.3    101.0   98.5    7.3    4.1   3.2
  Tadalafil                   94.2                  94.3                  95.7    3.1   2.5   3.4   91.9    96.6    99.1    7.9    5.6   3.4
  Aminotadalafil              98.4                  97.7                  98.7    3.2   3.9   4.7   92.6    102.3   99.9    5.4    3.5   1.3
  Acetaminotadalafil          99.2                  100.2                 101.3   4.6   6.6   4.2   90.3    99.4    100.3   7.2    5.7   3.2
  Demethyltadalafil           92.1                  100.7                 102.4   4.5   2.4   2.6   89.8    102.7   101.0   5.1    2.0   3.5
  Chloropretadalafil          106.7                 105.6                 105.0   2.6   2.2   3.5   98.0    105.6   105.7   10.5   2.9   2.1
  *N*-Octyltadalafil          107.8                 106.0                 98.1    7.9   0.6   4.8   95.4    103.9   97.9    6.5    5.7   1.8
  Yohimbine                   106.1                 104.0                 101.3   5.6   3.4   3.6   92.6    101.2   97.0    6.3    5.2   2.1
  Mirodenafil                 107.1                 100.2                 95.9    5.1   1.3   3.2   96.2    101.2   95.8    5.2    4.1   4.4
  Thioquinapiperifil          112.0                 105.0                 104.4   5.1   2.9   1.9   104.4   99.3    100.0   3.3    7.5   3.6
  Xanthoanthrafil             91.8                  99.5                  102.3   3.0   2.1   4.6   92.6    99.3    98.4    4.9    4.4   2.1

^a^ L: The lowest concentration in the calibration curve; ^b^ M: Medium concentration in the calibration curve; ^c^ H: The highest concentration in the calibration curve.
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###### 

Accurate masses and mass errors for fragment and precursor ions of PDE-5 inhibitors and their analogs.

  Compound              Elemental Composition        Measured Mass   Theoretical Mass   ∆*m* (mDa)   Error (ppm)
  --------------------- ---------------------------- --------------- ------------------ ------------ -------------
  Sildenafil            C~22~H~30~N~6~O~4~S ^a^      238.1087 ^b^    238.1100 ^b^       −1.3         −5.46
  C~17~H~20~N~4~O~4~S   377.1263                     377.1278        −1.5               −3.98        
  C~17~H~19~N~4~O~2~    312.1573                     312.1581        −0.8               −2.56        
  C~15~H~15~N~4~O~2~    284.1221                     284.1268        −4.7               −16.54       
  Thiosildenafil        C~22~H~30~N~6~O~3~S~2~ ^a^   246.0977 ^b^    246.0983 ^b^       −0.6         −2.50
  C~17~H~19~N~4~OS      328.1344                     328.1352        −0.8               −2.44        
  C~15~H~15~N~4~OS      300.1022                     300.1039        −1.7               −5.66        
  Vardenafil            C~23~H~32~N~6~O~4~S ^a^      245.1168 ^b^    245.1176 ^b^       −0.8         −3.26
  C~17~H~19~N~4~O~2~    312.1555                     312.1581        −2.6               −8.33        
  C~15~H~15~N~4~O~2~    284.1253                     284.1268        −1.5               −5.28        
  C~8~H~10~N~2~O        151.0877                     151.0866        1.1                7.28         
  Tadalafil             C~22~H~19~N~3~O~4~ ^a^       390.1454        390.1448           0.6          1.54
  C~15~H~13~N~3~O~2~    268.1050                     268.1081        −3.1               −11.56       
  C~17~H~11~NO~2~       262.0866                     262.0863        0.3                1.14         
  C~14~H~13~N~3~O       240.1099                     240.1131        −3.2               −13.33       
  C~12~H~8~N~2~O        197.0707                     197.0709        −0.2               −1.01        
  C~11~H~8~N~2~         169.0736                     169.0760        −2.4               −14.19       
  C~8~H~6~O~2~          135.0451                     135.0441        1.0                7.40         
  Mirodenafil           C~26~H~37~N~5~O~5~S ^a^      266.6326 ^b^    266.6330 ^b^       −0.4         −1.50
  C~20~H~24~N~3~O~2~    339.1914                     339.1941        −2.7               −7.96        
  C~17~H~18~N~3~O~2~    297.1444                     297.1472        −2.8               −9.42        
  C~23~H~31~N~5~O~5~S   245.6061 ^b^                 245.6096 ^b^    −3.5               −14.25       
  C~23~H~29~N~5~O~4~S   236.6006 ^b^                 236.6043 ^b^    −3.7               −15.64       
  Xanthoanthrafil       C~19~H~23~N~3~O~6~           390.1660        390.1660           0.0          0.00
  C~9~H~10~O~2~         151.0740                     151.0754        −1.4               18.17        
  Thioquinapiperifil    C~24~H~28~N~6~OS ^a^         225.1093 ^b^    225.1095 ^b^       −0.2         −0.89
  C~11~H~11~N~5~S       246.0774                     246.0808        −3.4               −13.82       
  C~9~H~7~N~5~S         218.0493                     218.0495        −0.2               −0.92        
  C~13~H~17~NO          204.1343                     204.1383        −4.0               −19.59       
  Yohimbine             C~21~H~26~N~2~O~3~ ^a^       355.2017        355.2016           0.1          0.28
  C~11~H~17~NO~3~       212.1248                     212.1281        −3.3               −15.56       
  C~11~H~15~NO~2~       194.1150                     194.1176        −2.6               −13.39       
  C~10~H~9~N            144.0803                     144.0808        −0.5               −3.47        
  C~10~H~13~NO~2~       180.1015                     180.1019        −0.4               −2.22        
  C~10~H~11~NO          162.0900                     162.0913        −1.3               −8.02        
  C~9~H~11~N            134.0955                     134.0964        −0.9               −6.71        

^a^ Precursor ion; ^b^ Multiply charged protonated ion \[M + 2H\]^2+^~.~

[^1]: These authors contributed equally to this work.
